Pjevic, Marija Dusanovic (57208618251)Marija Dusanovic (57208618251)PjevicBumbasirevic, Ljiljana Beslac (57210616177)Ljiljana Beslac (57210616177)BumbasirevicVojvodic, Ljubica (57208622507)Ljubica (57208622507)VojvodicGrk, Milka (57208632180)Milka (57208632180)GrkMaksimovic, Nela (36461365500)Nela (36461365500)MaksimovicDamnjanovic, Tatjana (13008423100)Tatjana (13008423100)DamnjanovicNovakovic, Ivana (6603235567)Ivana (6603235567)NovakovicKacar, Katarina (12647164500)Katarina (12647164500)KacarPesic, Milica (59602232000)Milica (59602232000)PesicPerovic, Dijana (55251514500)Dijana (55251514500)PerovicSavic, Milan (58596282700)Milan (58596282700)SavicMaksic, Veljko (57208629610)Veljko (57208629610)MaksicTrickovic, Jelena (59144740300)Jelena (59144740300)TrickovicJekic, Biljana (6603561846)Biljana (6603561846)Jekic2025-06-122025-06-122019https://doi.org/10.18433/jpps30339https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065294544&doi=10.18433%2fjpps30339&partnerID=40&md5=9607988e6da9df7e9dfbb2c779921b97https://remedy.med.bg.ac.rs/handle/123456789/5875Purpose: Treatment of Ischemic stroke (IS) in acute phase is based on the use of thrombolytic rt-PA therapy. We aimed to determine whether different alleles and genotypes of I/D ACE gene and 4G/5G PAI-1 gene polymorphisms may influence outcome of rt-PA therapy in patients with IS and the occurrence of haemorrhagic transformation (HT). Methods: Our study included 94 consecutive patients with IS treated with rt-PA. Modified Rankin Scale (mRS) at 3rd month after IS was used to determine the stroke outcome, with scores 0-1 defining the favourable outcome, and scores 2-6 defining poor outcome. Genotypisation of the ACE-1 I/D polymorphism was performed by polymerase chain reaction and of the PAI-1 4G/5G polymorphism by polymerase chain reaction - restriction fragment length analysis. Results: Regarding PAI-I 4G/5G polymorphism, 44 patients (46.8%) were heterozygotes, and the number of 4G/4G and 5G/5G homozygotes was the same – 25 each (26.6%). Number of heterozygotes for the ACE I/D polymorphism was 54 (57.4%), 9 patients (9.6%) had II, and 31 (33%) DD genotypes. A favourable outcome was recorded in 26 (28.0%) and the poor outcome in 67 (72.0%) patients. Favourable and poor outcome groups did not differ significantly in PAI-1 4G/5G and ACE I/D polymorphisms genotype or allele frequencies. There was a statistically significant difference in the occurrence of HT between patients with ACE II and patients with ACE ID or DD genotypes (p=0.035). Conclusion: Results of our study suggest that stroke patients with ACE II genotype, treated with rt-PA, may be at risk of HT. © 2019, MDPI AG. All rights reserved.